Insulet price target raised to $208 from $163 at Stifel

Stifel raised the firm’s price target on Insulet to $208 from $163 and keeps a Hold rating on the shares. The firm recently conducted its second annual U.S. Insulin Pump Survey, the analyst tells investors. The survey was largely positive for Insulet, which is highlighted by sustained new patient share leadership, the firm says. Before taking a more positive outlook on the company, however, Stifel would have liked to have seen even-higher share gains than previously modeled and/or evidence the firm is underestimating incremental opportunities, but the survey did not provide evidence of either.